黑料网

Journal of Pharmacokinetics & Experimental Therapeutics
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Case Report   
  • J Pharmacokinet Exp Ther, Vol 6(3): 144
  • DOI: 10.4172/jpet.1000144

A Study of CYP2C19 Activity in Populations of European and Japanese Ancestry Using a Physiologically 10.4172/jpet.1000145Based Pharmacokinetic Model of Clopidogrel

Naveen Pereira*
MD, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
*Corresponding Author : Naveen Pereira, MD, Department of Cardiovascular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA, Email: preira.naven@mayo.edu

Received Date: Jun 02, 2022 / Published Date: Jun 28, 2022

Abstract

Clopidogrel treatment response is linked to CYP2C19 activity, which is measured by the active H4 metabolite. The researchers wanted to create a physiologically based pharmacokinetic (PBPK) model of clopidogrel and its metabolites for European ancestry populations, predict pharmacokinetics in the Japanese population using the CYP2C19 phenotype, and look into the impact of clinical and demographic parameters. Using plasma data from previous research, a PBPK model was created and proven to describe the two metabolic routes of clopidogrel (H4 metabolite, acyl glucuronide metabolite) for a population of European ancestry

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top